Primary bone marrow Epstein–Barr virus-associated polymorphic B-cell lymphoproliferative disorder
Wei Wang
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Search for more papers by this authorBrenda Mai
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Search for more papers by this authorHaval Ali
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Search for more papers by this authorBadal U. Savariya
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Search for more papers by this authorCorresponding Author
Lei Chen
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Correspondence
Lei Chen, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center at Houston, 1515 Holcombe Blvd, Houston, Texas 77030, USA.
Email: [email protected]
Search for more papers by this authorWei Wang
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Search for more papers by this authorBrenda Mai
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Search for more papers by this authorHaval Ali
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Search for more papers by this authorBadal U. Savariya
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Search for more papers by this authorCorresponding Author
Lei Chen
Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, Texas, USA
Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Correspondence
Lei Chen, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center at Houston, 1515 Holcombe Blvd, Houston, Texas 77030, USA.
Email: [email protected]
Search for more papers by this author
REFERENCES
- 1Natkunam Y, Gratzinger D, Chadburn A, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018; 132(18): 1871-1878.
- 2Natkunam Y, Goodlad JR, Chadburn A, et al. EBV-positive B-cell proliferations of varied malignant potential: 2015 SH/EAHP workshop report-part 1. Am J Clin Pathol. 2017; 147(2): 129-152.
- 3Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol. 2005; 23(2): 61-67.
- 4Vakiani E, Basso K, Klein U, et al. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol. 2008; 26(4): 199-211.
- 5Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013; 91(1): 20-28.
- 6Hoshida Y, Xu J, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007; 34(2): 322-331.
- 7Satou A, Tabata T, Suzuki Y, et al. Nodal EBV-positive polymorphic B cell lymphoproliferative disorder with plasma cell differentiation: clinicopathological analysis of five cases. Virchows Arch. 2021; 478(5): 969-976.
- 8Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer; 2017.
- 9Nagar VS, Kadu R, Chauhan SG, et al. Clinically HIV but negative serology: thinks of idiopathic CD4+ lymphocytopenia. Indian J Crit Care Med. 2016; 20(6): 371-373.
- 10Abendroth MD, Bayerl MG, Wilkinson MJ, Claxton DF, Specht CS. Orbital Epstein-Barr virus-positive polymorphic B-cell lymphoproliferative disorder in an apparently immunocompetent woman. Ocul Oncol Pathol. 2017; 4(1): 61-65.
- 11Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004; 202(1): 60-69.
- 12de Jong D, Roemer MG, Chan JK, et al. B-cell and classical Hodgkin lymphomas associated with immunodeficiency: 2015 SH/EAHP workshop report-part 2. Am J Clin Pathol. 2017; 147(2): 153-170.
